PT2050453E - Combinações farmacêuticas de meloxicam, tramadol e paracetamol - Google Patents
Combinações farmacêuticas de meloxicam, tramadol e paracetamol Download PDFInfo
- Publication number
- PT2050453E PT2050453E PT08170195T PT08170195T PT2050453E PT 2050453 E PT2050453 E PT 2050453E PT 08170195 T PT08170195 T PT 08170195T PT 08170195 T PT08170195 T PT 08170195T PT 2050453 E PT2050453 E PT 2050453E
- Authority
- PT
- Portugal
- Prior art keywords
- meloxicam
- paracetamol
- combination
- codeine
- daily dose
- Prior art date
Links
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 title claims description 56
- 229960001929 meloxicam Drugs 0.000 title claims description 56
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title claims description 55
- 229960005489 paracetamol Drugs 0.000 title claims description 52
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 title claims description 13
- 229960004380 tramadol Drugs 0.000 title claims description 13
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 title claims description 13
- 208000002193 Pain Diseases 0.000 claims description 27
- 230000036407 pain Effects 0.000 claims description 27
- 239000004480 active ingredient Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 230000000917 hyperalgesic effect Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 206010037660 Pyrexia Diseases 0.000 claims description 7
- 230000000307 algesic effect Effects 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 208000000112 Myalgia Diseases 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 94
- 229960004126 codeine Drugs 0.000 description 47
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 47
- 230000003070 anti-hyperalgesia Effects 0.000 description 30
- 241000700159 Rattus Species 0.000 description 26
- 239000003795 chemical substances by application Substances 0.000 description 26
- 208000028867 ischemia Diseases 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 208000004454 Hyperalgesia Diseases 0.000 description 11
- 208000035154 Hyperesthesia Diseases 0.000 description 11
- 230000000202 analgesic effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000010410 reperfusion Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 230000036592 analgesia Effects 0.000 description 7
- 230000003502 anti-nociceptive effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 7
- 230000002411 adverse Effects 0.000 description 6
- 230000001473 noxious effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000020341 sensory perception of pain Effects 0.000 description 5
- 230000001052 transient effect Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000007659 motor function Effects 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical group O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 3
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 description 3
- 229920001800 Shellac Polymers 0.000 description 3
- 235000019486 Sunflower oil Nutrition 0.000 description 3
- 229960004415 codeine phosphate Drugs 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000004208 shellac Substances 0.000 description 3
- 235000013874 shellac Nutrition 0.000 description 3
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 3
- 229940113147 shellac Drugs 0.000 description 3
- 239000002600 sunflower oil Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 229940124638 COX inhibitor Drugs 0.000 description 2
- 101150071146 COX2 gene Proteins 0.000 description 2
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 241000581650 Ivesia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101150000187 PTGS2 gene Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- -1 for example Substances 0.000 description 2
- 230000036449 good health Effects 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000036515 potency Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 101100168274 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-3 gene Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000000188 Vaccinium ovalifolium Species 0.000 description 1
- 101000942305 Zea mays Cytokinin dehydrogenase 1 Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 239000003965 antinociceptive agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000001432 effect on motor function Effects 0.000 description 1
- 230000006397 emotional response Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000026416 response to pain Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003239 susceptibility assay Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA200201395 | 2002-02-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2050453E true PT2050453E (pt) | 2012-01-03 |
Family
ID=27758232
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT08170195T PT2050453E (pt) | 2002-02-19 | 2003-02-14 | Combinações farmacêuticas de meloxicam, tramadol e paracetamol |
| PT03706774T PT1478366E (pt) | 2002-02-19 | 2003-02-14 | Combinações farmacêuticas de meloxicam, fosfato de codeína e paracetamol |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT03706774T PT1478366E (pt) | 2002-02-19 | 2003-02-14 | Combinações farmacêuticas de meloxicam, fosfato de codeína e paracetamol |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20050090517A1 (enExample) |
| EP (2) | EP2050453B1 (enExample) |
| JP (1) | JP2005519936A (enExample) |
| CN (1) | CN100418533C (enExample) |
| AP (1) | AP1862A (enExample) |
| AT (2) | ATE524186T1 (enExample) |
| AU (1) | AU2003208485B2 (enExample) |
| CA (1) | CA2476939C (enExample) |
| CY (1) | CY1108839T1 (enExample) |
| DE (1) | DE60325020D1 (enExample) |
| DK (1) | DK1478366T3 (enExample) |
| EG (1) | EG24845A (enExample) |
| ES (2) | ES2376500T3 (enExample) |
| IL (2) | IL163637A0 (enExample) |
| NZ (1) | NZ535500A (enExample) |
| OA (1) | OA12778A (enExample) |
| PT (2) | PT2050453E (enExample) |
| SI (1) | SI1478366T1 (enExample) |
| WO (1) | WO2003070251A1 (enExample) |
| ZA (1) | ZA200407485B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005094832A1 (en) * | 2004-04-01 | 2005-10-13 | Boehringer Ingelheim International Gmbh | Compositions comprising meloxicam |
| WO2005117895A2 (en) * | 2004-06-04 | 2005-12-15 | Boehringer Ingelheim International Gmbh | Compositions comprising meloxicam |
| ITMI20060983A1 (it) * | 2006-05-18 | 2007-11-19 | Formevet S P A | Composizioni farmaceutiche veterinarie per il trattamento del dolore e dell'inifiamazione |
| WO2007138466A2 (en) * | 2006-06-01 | 2007-12-06 | Wockhardt Ltd | Pharmaceutical compositions comprising meloxicam and tramadol combination |
| US20080031950A1 (en) * | 2007-04-27 | 2008-02-07 | Nectid Inc. | Novel anelgesic combination |
| US20080026054A1 (en) * | 2007-04-27 | 2008-01-31 | Nectid Inc. | Novel anelgesic combination |
| EP2177215A1 (en) | 2008-10-17 | 2010-04-21 | Laboratorios Del. Dr. Esteve, S.A. | Co-crystals of tramadol and NSAIDs |
| EP2311446A1 (en) * | 2009-10-16 | 2011-04-20 | Laboratorios Del. Dr. Esteve, S.A. | Compositions comprising Tramadol and Celecoxib in the treatment of pain |
| IT1398321B1 (it) * | 2010-02-26 | 2013-02-22 | Formevet Spa Ora Formevet Srl | Associazione tra un analgesico ad azione centrale e un antinfiammatorio inibitore selettivo della cicloossigenasi 2 per il trattamento dell'infiammazione e del dolore in campo veterinario |
| EP2392319A1 (en) * | 2010-06-04 | 2011-12-07 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical compositions of co-crystals of tramadol and coxibs |
| WO2015004505A1 (es) * | 2013-07-11 | 2015-01-15 | More Pharma Corporation, S. De R.L. De C.V. | Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio |
| MX2018013070A (es) | 2017-12-29 | 2019-10-15 | Gruenenthal Gmbh | Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor. |
| WO2020061475A2 (en) * | 2018-09-21 | 2020-03-26 | The Johns Hopkins University | Compositions and methods for treating metabolic disorders |
| CN115300515A (zh) * | 2022-08-11 | 2022-11-08 | 南京红地生物科技有限公司 | 一种含有美洛昔康和盐酸曲马多的长效注射液 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA845785B (en) * | 1983-06-10 | 1985-03-27 | Adcock Ingram Lab Ltd | Pharmaceutical unit |
| ZA893422B (en) * | 1988-02-24 | 1991-01-30 | Adcock Ingram Lab Ltd | Pharmaceutical composition |
| AU3990895A (en) * | 1995-12-05 | 1997-06-27 | Adcock Ingram Limited | Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic |
| RS49982B (sr) * | 1997-09-17 | 2008-09-29 | Euro-Celtique S.A., | Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2 |
| FR2770131A1 (fr) * | 1997-10-27 | 1999-04-30 | Union Pharma Scient Appl | Nouvelle association pharmaceutique a activite analgesique |
| US6375957B1 (en) * | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| UA55507C2 (uk) * | 1997-12-22 | 2003-04-15 | Еро-Селтік, С.А. | Лікарська форма для перорального введення та спосіб запобігання зловживанню пероральною опіоїдною композицією |
| CA2409927A1 (en) * | 2000-05-31 | 2001-12-06 | Warner-Lambert Company | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic |
| IL153303A0 (en) * | 2000-06-13 | 2003-07-06 | Wyeth Corp | Analgesic and anti-inflammatory compositions conaining cox-2 inhibitors |
-
2003
- 2003-02-14 AT AT08170195T patent/ATE524186T1/de not_active IP Right Cessation
- 2003-02-14 JP JP2003569207A patent/JP2005519936A/ja active Pending
- 2003-02-14 DE DE60325020T patent/DE60325020D1/de not_active Expired - Lifetime
- 2003-02-14 OA OA1200400220A patent/OA12778A/en unknown
- 2003-02-14 PT PT08170195T patent/PT2050453E/pt unknown
- 2003-02-14 ES ES08170195T patent/ES2376500T3/es not_active Expired - Lifetime
- 2003-02-14 EP EP08170195A patent/EP2050453B1/en not_active Expired - Lifetime
- 2003-02-14 PT PT03706774T patent/PT1478366E/pt unknown
- 2003-02-14 NZ NZ535500A patent/NZ535500A/en not_active IP Right Cessation
- 2003-02-14 CA CA2476939A patent/CA2476939C/en not_active Expired - Lifetime
- 2003-02-14 AP APAP/P/2004/003134A patent/AP1862A/en active
- 2003-02-14 SI SI200331530T patent/SI1478366T1/sl unknown
- 2003-02-14 AT AT03706774T patent/ATE415971T1/de active
- 2003-02-14 WO PCT/IB2003/000500 patent/WO2003070251A1/en not_active Ceased
- 2003-02-14 AU AU2003208485A patent/AU2003208485B2/en not_active Ceased
- 2003-02-14 US US10/505,291 patent/US20050090517A1/en not_active Abandoned
- 2003-02-14 ES ES03706774T patent/ES2318113T3/es not_active Expired - Lifetime
- 2003-02-14 IL IL16363703A patent/IL163637A0/xx unknown
- 2003-02-14 EP EP03706774A patent/EP1478366B1/en not_active Expired - Lifetime
- 2003-02-14 DK DK03706774T patent/DK1478366T3/da active
- 2003-02-14 CN CNB038085321A patent/CN100418533C/zh not_active Expired - Fee Related
-
2004
- 2004-08-19 IL IL163637A patent/IL163637A/en active IP Right Grant
- 2004-08-19 EG EGNA2004000074 patent/EG24845A/xx active
- 2004-09-17 ZA ZA2004/07485A patent/ZA200407485B/en unknown
-
2009
- 2009-02-27 CY CY20091100239T patent/CY1108839T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003070251A1 (en) | 2003-08-28 |
| OA12778A (en) | 2006-07-06 |
| AP1862A (en) | 2008-07-07 |
| IL163637A0 (en) | 2005-12-18 |
| CY1108839T1 (el) | 2014-07-02 |
| DK1478366T3 (da) | 2009-03-30 |
| EP1478366A1 (en) | 2004-11-24 |
| NZ535500A (en) | 2006-09-29 |
| AP2004003134A0 (en) | 2004-09-30 |
| AU2003208485B2 (en) | 2009-05-28 |
| EP2050453A1 (en) | 2009-04-22 |
| EP1478366B1 (en) | 2008-12-03 |
| DE60325020D1 (de) | 2009-01-15 |
| ATE415971T1 (de) | 2008-12-15 |
| PT1478366E (pt) | 2009-03-10 |
| ATE524186T1 (de) | 2011-09-15 |
| JP2005519936A (ja) | 2005-07-07 |
| IL163637A (en) | 2010-11-30 |
| US20050090517A1 (en) | 2005-04-28 |
| EG24845A (en) | 2010-10-21 |
| SI1478366T1 (sl) | 2009-06-30 |
| CN1646133A (zh) | 2005-07-27 |
| ZA200407485B (en) | 2005-12-28 |
| ES2318113T3 (es) | 2009-05-01 |
| EP2050453B1 (en) | 2011-09-14 |
| CA2476939A1 (en) | 2003-08-28 |
| CN100418533C (zh) | 2008-09-17 |
| ES2376500T3 (es) | 2012-03-14 |
| AU2003208485A1 (en) | 2003-09-09 |
| CA2476939C (en) | 2012-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2050453E (pt) | Combinações farmacêuticas de meloxicam, tramadol e paracetamol | |
| Alloui et al. | Paracetamol exerts a spinal, tropisetron-reversible, antinociceptive effect in an inflammatory pain model in rats | |
| Savage et al. | Preoperative nonsteroidal anti-inflammatory agents: review of the literature | |
| Martins et al. | Comparison of the effects of tramadol, codeine, and ketoprofen alone or in combination on postoperative pain and on concentrations of blood glucose, serum cortisol, and serum interleukin-6 in dogs undergoing maxillectomy or mandibulectomy | |
| Castañeda-Hernández et al. | Potentiation by caffeine of the analgesic effect of aspirin in the pain-induced functional impairment model in the rat | |
| Isik et al. | Effects of sugammadex and neostigmine on renal biomarkers | |
| Tariq et al. | Effects of subchronic versus acute in utero exposure to dexmedetomidine on foetal developments in rats | |
| DeLeo et al. | The differentiation of NSAIDs and prostaglandin action using a mechanical visceral pain model in the rat | |
| Rehni et al. | Modulation of histone deacetylase attenuates naloxone-precipitated opioid withdrawal syndrome | |
| Welsh et al. | Effects of non-steroidal anti-inflammatory drugs on the hyperalgesia to noxious mechanical stimulation induced by the application of a tourniquet to a forelimb of sheep | |
| Porter | Factors determining efficacy of NSAIDs | |
| Melnick et al. | Impairment of spatial learning following preweaning cocaine exposure in the adult rat | |
| HK1126400A (en) | Pharmaceutical combinations of meloxicam, tramadol and paracetamol | |
| Fruhwald et al. | Differential reversal of drug-induced small bowel paralysis by cerulein and neostigmine | |
| Khan et al. | Exploration for the opioidergic, GABAergic and histaminergic potentials of synthesized Schiff’s base derivatives: An in-vivo approach | |
| Moberly et al. | A randomized, double-blind, one-week study comparing effects of a novel COX-2 inhibitor and naproxen on the gastric mucosa | |
| Ambrosio et al. | SIAARTI recommendations on the assessment and treatment of chronic cancer pain | |
| Ortiz et al. | Synergistic relaxing effect of the paracetamol and pyrilamine combination in isolated human myometrium | |
| Schellack et al. | An overview of muscle pain | |
| Olivares-Muñoz et al. | Effect of acetaminophen on hepatic enzymes and renal analytes of ovary-hysterectomized dogs | |
| Mogole et al. | Muscle pain | |
| EP3556363A1 (en) | Use of carbamate compound for prevention, alleviation or treatment of pruritus | |
| Karademir et al. | Evaluation of the vasorelaxant effect of Sugammadex on the arterial smooth muscle in rats. | |
| Xie et al. | Rapid emergence from dexmedetomidine sedation in Sprague Dawley rats by repurposing an α | |
| Ng | Advances in postoperative pain management |